Today at ADA 2021, ABCD is pleased to announce the launch of the ABCD nationwide oral semaglutide audit. As you will know, the clinical trials with semaglutide suggest that it may be more effective than the other GLP-1 receptor agonists.  Results from the ABCD semaglutide audit, presented this weekend at ADA 2021, have demonstrated significant reductions in HbA1c and weight following commencement of semaglutide in a real-world cohort that was heavier with higher baseline HbA1c levels than those in clinical trials.

King's College London are seeking applications for the prestigious RD Lawrence Chair. For further information please see the detailed advertisement.

The ABCD Empagliflozin audit has provided valuable insights into empagliflozin use in UK based real-world practice. Additionally, data from the other SGLT2 audit programmes has demonstrated reductions in ALT as a marker of liver inflammation following commencement, with reductions much greater in those with elevated levels at baseline.

We are pleased to be presenting our first analysis from the ABCD Semaglutide audit at the American Diabetes Association Scientific Session virtual session this weekend.

SAS doctors play a vital role in the delivery of NHS services but can sometimes be overlooked when it comes to career development and recognition.
 
Join this webinar to hear from the chair of the RCP SAS doctor network and senior RCP officers on the latest national changes for SAS doctors, the work of the RCP SAS doctor network and how the College can support you now and in the future to build a successful and enjoyable career.

About the event

The event will focus on how SAS doctors can:

The Joint British Diabetes Societies (JBDS) for Inpatient Care group was created in 2008 to ‘deliver a set of diabetes inpatient guidelines and proposed standards of care within secondary care organisations’, with the overall aim of improving inpatient diabetes care through the development and use of high quality evidence based guidelines, and through better inpatient care pathways.

Yue Ruan, Robert E J Ryder, Parijat De, Benjamin C T Field, Parth Narendran, Ahmed Iqbal, Rajiv Gandhi, Sophie Harris, Dinesh Nagi, Umaira Aziz, Efthimia Karra, Sandip Ghosh, Wasim Hanif, Amy E Edwards, Mansoor Zafar, Umesh Dashora, Kinga A Várnai, Jim Davies, Sarah H Wild, Emma G Wilmot, David Webb, Kamlesh Khunti, Rustam Rea, ABCD Covid-19 audit group

Dinesh Nagi, Robert EJ Ryder, Yue Ruan, Benjamin CT Field, Parth Narendran, Rajiv Gandhi, Sophie Harris, Kinga A Várnai, Jim Davies, Sarah H Wild, Emma G Wilmot, Kamlesh Khunti, Rustam Rea on behalf of the ABCD Covid-19 audit group

Canagliflozin, Dapagliflozin and Empagliflozin